BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th
BridgeBio (Nasdaq: BBIO) will release topline results from the ADH1 CALIBRATE Phase 3 trial before the market opens on Wednesday, October 28, 2025. Management will discuss the data on a conference call at 8:00 a.m. ET the same day.
Investors can access a live webcast via the company’s Investors > Events and Presentations page and a replay will be available on the BridgeBio website for 90 days after the event.
BridgeBio (Nasdaq: BBIO) rilascerà i risultati di punta dello studio ADH1 CALIBRATE Phase 3 prima dell'apertura del mercato di mercoledì 28 ottobre 2025. Il management discuterà i dati durante una conferenza telefonica alle 8:00 ET dello stesso giorno.
Gli investitori possono accedere a una trasmissione in diretta tramite la pagina Investitori > Eventi e Presentazioni dell’azienda e una replica sarà disponibile sul sito BridgeBio per 90 giorni dopo l’evento.
BridgeBio (Nasdaq: BBIO) publicará los resultados principales del ensayo ADH1 CALIBRATE Phase 3 antes de la apertura del mercado el miércoles 28 de octubre de 2025. La dirección discutirá los datos en una llamada de conferencia a las 8:00 a. m. ET ese mismo día.
Los inversores pueden acceder a una transmisión en vivo a través de la página de Inversores > Eventos y Presentaciones de la empresa y se podrá disponer de una retransmisión en el sitio web de BridgeBio durante 90 días después del evento.
BridgeBio (나스닥: BBIO)는 ADH1 CALIBRATE 3상 시험의 탑라인 결과를 2025년 10월 28일 수요일 시장 개장 전에 발표합니다. 경영진은 같은 날 동부 표준시 8:00에 데이터에 대해 컨퍼런스 콜로 논의할 예정입니다.
투자자들은 회사의 투자자 > 이벤트 및 프리젠테이션 페이지를 통해 라이브 생방송에 접속할 수 있으며 이벤트 후 BridgeBio 웹사이트에서 90일 동안 재생본을 이용할 수 있습니다.
BridgeBio (Nasdaq: BBIO) publiera les résultats principaux de l’essai ADH1 CALIBRATE Phase 3 avant l’ouverture du marché le mercredi 28 octobre 2025. La direction discutera des données lors d’une conférence téléphonique à 8 h 00 HAE le même jour.
Les investisseurs peuvent accéder à une webdiffusion en direct via la page Investisseurs > Événements et Présentations de l’entreprise et une rediffusion sera disponible sur le site BridgeBio pendant 90 jours après l’événement.
BridgeBio (Nasdaq: BBIO) wird die Endergebnisse der ADH1 CALIBRATE Phase-3-Studie vor Börseneröffnung am Mittwoch, dem 28. Oktober 2025 bekannt geben. Das Management wird die Daten am selben Tag in einer Telefonkonferenz um 8:00 Uhr ET diskutieren.
Investoren können über die Seite Investors > Events and Presentations eine Live-Webcast aufrufen, und eine Wiedergabe wird auf der BridgeBio-Website für 90 Tage nach der Veranstaltung verfügbar sein.
ستصدر BridgeBio (ناسداك: BBIO) النتائج الرئيسية من تجربة ADH1 CALIBRATE المرحلة 3 قبل افتتاح السوق يوم الأربعاء 28 أكتوبر 2025. ستناقش الإدارة البيانات في مكالمة مؤتمر في الساعة 8:00 صباحاً بتوقيت شرق الولايات المتحدة نفسه اليوم.
يمكن للمستثمرين الوصول إلى بث مباشر عبر صفحة المستثمرون > الأحداث والعروض التقديمية للشركة وسيكون هناك إعادة عرض متاحة على موقع BridgeBio لمدة 90 يوماً بعد الحدث.
BridgeBio（纳斯达克: BBIO） 将于 2025年10月28日周三市场开盘前公布 ADH1 CALIBRATE 第3阶段试验的 topline 结果。管理层将于同日东部时间 8:00 通过电话会议讨论数据。
投资者可以通过公司页面的 投资者 > 事件与演示 访问现场直播，事件结束后 BridgeBio 网站将提供回放，回放将持续 90 天。
- None.
- None.
PALO ALTO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced plans to release topline results of the autosomal dominant hypocalcemia type 1 (ADH1) CALIBRATE Phase 3 trial before the market opens on Wednesday, October 28, 2025. Members of management will host a conference call to discuss the data at 8:00 a.m. ET the same day.
To access the live webcast for BridgeBio's calls, please visit the “Events and Presentations” page within the Investors section of the BridgeBio website at https://investor.bridgebio.com. A replay of the webcasts will be available on the BridgeBio website for 90 days following the event.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, Instagram and YouTube.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com
FAQ
When will BridgeBio (BBIO) release ADH1 CALIBRATE Phase 3 topline results?
What time is the BridgeBio (BBIO) conference call to discuss ADH1 CALIBRATE results?
Where can investors watch the BridgeBio (BBIO) webcast for the ADH1 CALIBRATE results?
How long will the replay of BridgeBio (BBIO) ADH1 CALIBRATE webcast remain available?
What is the ADH1 CALIBRATE study that BridgeBio (BBIO) is reporting on?
Will BridgeBio (BBIO) provide detailed data during the October 28, 2025 call?
